The Hepatitis C Virus Life Cycle as a Target for New Antiviral Therapies

Gastroenterology

Volumn 132, Issue 5, 2007, Pages 1979-1998

  Pawlotsky, Jean Michel ^a,b   Chevaliez, Stéphane ^a,b   McHutchison, John G ^c  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM   (France)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 831; ACH 1095; ACH 806; ANTIVIRUS AGENT; AVI 4065; CASTANOSPERMINE 6 BUTYRATE; CILUPREVIR; CIVACIR; DEBIO 025; GLYCOPROTEIN E1; GLYCOPROTEIN E2; GLYCOSAMINOGLYCAN; GS 9132; HCV 796; HCV AB 65; HCV AB 68; HEPATITIS ANTIBODY; HEPTAZYME; ISIS 14803; ITMN 191; JTK 003; MK 0608; MONOCLONAL ANTIBODY; NIM 811; NM 107; OLIGOMER; PROTEINASE INHIBITOR; QU 663; R 1626; RIBOZYME; SCH 503034; SERINE PROTEINASE INHIBITOR; TT 033; UNCLASSIFIED DRUG; UNINDEXED DRUG; UT 2311; UT 231B; VALOPICITABINE; VGX 410C; VIRUS RNA; VX 950;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; HEPATITIS C; HUMAN; NONHUMAN; PRIORITY JOURNAL; RNA TRANSLATION; VIRUS REPLICATION;

EID: 34247895578     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.03.116     Document Type: Article

References (224)

1. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36 (2002) S3-S20
2. Bartosch B., Dubuisson J., and Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197 (2003) 633-642
3. Nielsen S.U., Bassendine M.F., Burt A.D., Bevitt D.J., and Toms G.L. Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol 85 (2004) 1497-1507
4. Deleersnyder V., Pillez A., Wychowski C., Blight K., Xu J., Hahn Y.S., Rice C.M., and Dubuisson J. Formation of native hepatitis C virus glycoprotein complexes. J Virol 71 (1997) 697-704
5. Cocquerel L., Meunier J.C., Pillez A., Wychowski C., and Dubuisson J. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol 72 (1998) 2183-2191
6. Cocquerel L., Wychowski C., Minner F., Penin F., and Dubuisson J. Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins. J Virol 74 (2000) 3623-3633
7. Ciczora Y., Callens N., Penin F., Pecheur E.I., and Dubuisson J. Transmembrane domains of hepatitis C virus envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry. J Virol 81 (2007) 2372-2381
8. Weiner A.J., Christopherson C., Hall J.E., Bonino F., Saracco G., Brunetto M.R., Crawford K., Marion C.D., Crawford K.A., Venkatakrishna S., and Houghton M. Sequence variation in hepatitis C viral isolates. J Hepatol 13 Suppl 4 (1991) S6-S14
9. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., Shimizu Y., Shapiro M., Alter H.J., and Purcell R.H. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 93 (1996) 15394-15399
10. Zibert A., Kraas W., Meisel H., Jung G., and Roggendorf M. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol 71 (1997) 4123-4127
11. Penin F., Combet C., Germanidis G., Frainais P.O., Deleage G., and Pawlotsky J.M. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75 (2001) 5703-5710
12. Flint M., and McKeating J.A. The role of the hepatitis C virus glycoproteins in infection. Rev Med Virol 10 (2000) 101-117
13. Rosa D., Campagnoli S., Moretto C., Guenzi E., Cousens L., Chin M., Dong C., Weiner A.J., Lau J.Y., Choo Q.L., Chien D., Pileri P., Houghton M., and Abrignani S. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 93 (1996) 1759-1763
14. Bartosch B., Vitelli A., Granier C., Goujon C., Dubuisson J., Pascale S., Scarselli E., Cortese R., Nicosia A., and Cosset F.L. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278 (2003) 41624-41630
15. Barth H., Schafer C., Adah M.I., Zhang F., Linhardt R.J., Toyoda H., Kinoshita-Toyoda A., Toida T., Van Kuppevelt T.H., Depla E., Von Weizsacker F., Blum H.E., and Baumert T.F. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278 (2003) 41003-41012
16. Bartosch B., Verney G., Dreux M., Donot P., Morice Y., Penin F., Pawlotsky J.M., Lavillette D., and Cosset F.L. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79 (2005) 8217-8229
17. Voisset C., Callens N., Blanchard E., Op De Beeck A., Dubuisson J., and Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 280 (2005) 7793-7799
18. Barth H., Schnober E.K., Zhang F., Linhardt R.J., Depla E., Boson B., Cosset F.L., Patel A.H., Blum H.E., and Baumert T.F. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol 80 (2006) 10579-10590
19. Walker C.M. Comparative features of hepatitis C virus infection in humans and chimpanzees. Springer Semin Immunopathol 19 (1997) 85-98
20. Major M.E., Dahari H., Mihalik K., Puig M., Rice C.M., Neumann A.U., and Feinstone S.M. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 39 (2004) 1709-1720
21. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., and Abrignani S. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
22. Petracca R., Falugi F., Galli G., Norais N., Rosa D., Campagnoli S., Burgio V., Di Stasio E., Giardina B., Houghton M., Abrignani S., and Grandi G. Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol 74 (2000) 4824-4830
23. Flint M., Thomas J.M., Maidens C.M., Shotton C., Levy S., Barclay W.S., and McKeating J.A. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol 73 (1999) 6782-6790
24. Meola A., Sbardellati A., Bruni Ercole B., Cerretani M., Pezzanera M., Ceccacci A., Vitelli A., Levy S., Nicosia A., Traboni C., McKeating J., and Scarselli E. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol 74 (2000) 5933-5938
25. Koutsoudakis G., Herrmann E., Kallis S., Bartenschlager R., and Pietschmann T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol 81 (2007) 588-598
26. Roccasecca R., Ansuini H., Vitelli A., Meola A., Scarselli E., Acali S., Pezzanera M., Ercole B.B., McKeating J., Yagnik A., Lahm A., Tramontano A., Cortese R., and Nicosia A. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol 77 (2003) 1856-1867
27. Cormier E.G., Tsamis F., Kajumo F., Durso R.J., Gardner J.P., and Dragic T. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A 101 (2004) 7270-7274
28. Masciopinto F., Freer G., Burgio V.L., Levy S., Galli-Stampino L., Bendinelli M., Houghton M., Abrignani S., and Uematsu Y. Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology 304 (2002) 187-196
29. Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., and Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21 (2002) 5017-5025
30. Krieger M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 108 (2001) 793-797
31. Babitt J., Trigatti B., Rigotti A., Smart E.J., Anderson R.G., Xu S., and Krieger M. Murine SR-BI, a high-density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem 272 (1997) 13242-13249
32. Silver D.L., Wang N., Xiao X., and Tall A.R. High-density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J Biol Chem 276 (2001) 25287-25293
33. von Hahn T., Lindenbach B.D., Boullier A., Quehenberger O., Paulson M., Rice C.M., and McKeating J.A. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 43 (2006) 932-942
34. Barth H., Cerino R., Arcuri M., Hoffmann M., Schurmann P., Adah M.I., Gissler B., Zhao X., Ghisetti V., Lavezzo B., Blum H.E., von Weizsacker F., Vitelli A., Scarselli E., and Baumert T.F. Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol 79 (2005) 5774-5785
35. Van Itallie C.M., and Anderson J.M. Claudins and epithelial paracellular transport. Annu Rev Physiol 68 (2006) 403-429
36. Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., Hatziloannou T., McKeating J.A., Bieniasz P.D., and Rice C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446 (2007) 801-805
37. Gardner J.P., Durso R.J., Arrigale R.R., Donovan G.P., Maddon P.J., Dragic T., and Olson W.C. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci U S A 100 (2003) 4498-4503
38. Pohlmann S., Zhang J., Baribaud F., Chen Z., Leslie G.J., Lin G., Granelli-Piperno A., Doms R.W., Rice C.M., and McKeating J.A. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 77 (2003) 4070-4080
39. Lozach P.Y., Amara A., Bartosch B., Virelizier J.L., Arenzana-Seisdedos F., Cosset F.L., and Altmeyer R. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem 279 (2004) 32035-32045
40. Lozach P.Y., Lortat-Jacob H., de Lacroix de Lavalette A., Staropoli I., Foung S., Amara A., Houles C., Fieschi F., Schwartz O., Virelizier J.L., Arenzana-Seisdedos F., and Altmeyer R. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 278 (2003) 20358-20366
41. Bashirova A.A., Geijtenbeek T.B., van Duijnhoven G.C., van Vliet S.J., Eilering J.B., Martin M.P., Wu L., Martin T.D., Viebig N., Knolle P.A., KewalRamani V.N., van Kooyk Y., and Carrington M. A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection. J Exp Med 193 (2001) 671-678
42. Ludwig I.S., Lekkerkerker A.N., Depla E., Bosman F., Musters R.J., Depraetere S., van Kooyk Y., and Geijtenbeek T.B. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J Virol 78 (2004) 8322-8332
43. Chung N.S., and Wasan K.M. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev 56 (2004) 1315-1334
44. Agnello V., Abel G., Elfahal M., Knight G.B., and Zhang Q.X. Hepatitis C virus and other flaviviridae viruses enter cells via low-density lipoprotein receptor. Proc Natl Acad Sci U S A 96 (1999) 12766-12771
45. Monazahian M., Bohme I., Bonk S., Koch A., Scholz C., Grethe S., and Thomssen R. Low-density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 57 (1999) 223-229
46. Wunschmann S., Medh J.D., Klinzmann D., Schmidt W.N., and Stapleton J.T. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 74 (2000) 10055-10062
47. Saunier B., Triyatni M., Ulianich L., Maruvada P., Yen P., and Kohn L.D. Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol 77 (2003) 546-559
48. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., and McKeating J.A. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100 (2003) 7271-7276
49. Tscherne D.M., Jones C.T., Evans M.J., Lindenbach B.D., McKeating J.A., and Rice C.M. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 80 (2006) 1734-1741
50. Blanchard E., Belouzard S., Goueslain L., Wakita T., Dubuisson J., Wychowski C., and Rouille Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 80 (2006) 6964-6972
51. Koutsoudakis G., Kaul A., Steinmann E., Kallis S., Lohmann V., Pietschmann T., and Bartenschlager R. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 80 (2006) 5308-5320
52. Yagnik A.T., Lahm A., Meola A., Roccasecca R.M., Ercole B.B., Nicosia A., and Tramontano A. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40 (2000) 355-366
53. Op De Beeck A., Voisset C., Bartosch B., Ciczora Y., Cocquerel L., Keck Z., Foung S., Cosset F.L., and Dubuisson J. Characterization of functional hepatitis C virus envelope glycoproteins. J Virol 78 (2004) 2994-3002
54. Lescar J., Roussel A., Wien M.W., Navaza J., Fuller S.D., Wengler G., Wengler G., and Rey F.A. The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 105 (2001) 137-148
55. Davis G.L., Nelson D.R., Terrault N., Pruett T.L., Schiano T.D., Fletcher C.V., Sapan C.V., Riser L.N., Li Y., Whitley R.J., and Gnann Jr. J.W. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 11 (2005) 941-949
56. Eren R., Landstein D., Terkieltaub D., Nussbaum O., Zauberman A., Ben-Porath J., Gopher J., Buchnick R., Kovjazin R., Rosenthal-Galili Z., Aviel S., Ilan E., Shoshany Y., Neville L., Waisman T., Ben-Moshe O., Kischitsky A., Foung S.K., Keck Z.Y., Pappo O., Eid A., Jurim O., Zamir G., Galun E., and Dagan S. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 80 (2006) 2654-2664
57. Schiano T.D., Charlton M., Younossi Z., Galun E., Pruett T., Tur-Kaspa R., Eren R., Dagan S., Graham N., Williams P.V., and Andrews J. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 12 (2006) 1381-1389
58. Galun E., Terrault N.A., Eren R., Zauberman A., Nussbaum O., Terkieltaub D., Zohar M., Buchnik R., Ackerman Z., Safadi R., Ashur Y., Misrachi S., Liberman Y., Rivkin L., and Dagan S. Clinical evaluation (phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J Hepatol 46 (2007) 37-44
59. Roccasecca R., Folgori A., Ercole B.B., Puntoriero G., Lahm A., Zucchelli S., Tafi R., Pezzanera M., Galfre G., Tramontano A., Mondelli M.U., Pessi A., Nicosia A., Cortese R., and Meola A. Mimotopes of the hypervariable region 1 of the hepatitis C virus induce cross-reactive antibodies directed against discontinuous epitopes. Mol Immunol 38 (2001) 485-492
60. Zucchelli S., Roccasecca R., Meola A., Ercole B.B., Tafi R., Dubuisson J., Galfre G., Cortese R., and Nicosia A. Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization. Hepatology 33 (2001) 692-703
61. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., and Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 309 (2005) 623-626
62. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., and Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 (2005) 791-796
63. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., and Chisari F.V. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102 (2005) 9294-9299
64. Helle F., Wychowski C., Vu-Dac N., Gustafson K.R., Voisset C., and Dubuisson J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem 281 (2006) 25177-25183
65. Brown E.A., Zhang H., Ping L.H., and Lemon S.M. Secondary structure of the 5' nontranslated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res 20 (1992) 5041-5045
66. Wang C., Le S.Y., Ali N., and Siddiqui A. An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the hepatitis C virus 5' noncoding region. RNA 1 (1995) 526-537
67. Honda M., Ping L.H., Rijnbrand R.C., Amphlett E., Clarke B., Rowlands D., and Lemon S.M. Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. Virology 222 (1996) 31-42
68. Friebe P., Lohmann V., Krieger N., and Bartenschlager R. Sequences in the 5' nontranslated region of hepatitis C virus required for RNA replication. J Virol 75 (2001) 12047-12057
69. Luo G., Xin S., and Cai Z. Role of the 5'-proximal stem-loop structure of the 5' untranslated region in replication and translation of hepatitis C virus RNA. J Virol 77 (2003) 3312-3318
70. Lukavsky P.J., Otto G.A., Lancaster A.M., Sarnow P., and Puglisi J.D. Structures of two RNA domains essential for hepatitis C virus internal ribosome entry site function. Nat Struct Biol 7 (2000) 1105-1110
71. Ji H., Fraser C.S., Yu Y., Leary J., and Doudna J.A. Coordinated assembly of human translation initiation complexes by the hepatitis C virus internal ribosome entry site RNA. Proc Natl Acad Sci U S A 101 (2004) 16990-16995
72. Otto G.A., and Puglisi J.D. The pathway of HCV IRES-mediated translation initiation. Cell 119 (2004) 369-380
73. Otto G.A., Lukavsky P.J., Lancaster A.M., Sarnow P., and Puglisi J.D. Ribosomal proteins mediate the hepatitis C virus IRES-HeLa 40S interaction. RNA 8 (2002) 913-923
74. Spahn C.M., Kieft J.S., Grassucci R.A., Penczek P.A., Zhou K., Doudna J.A., and Frank J. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40s ribosomal subunit. Science 291 (2001) 1959-1962
75. Sizova D.V., Kolupaeva V.G., Pestova T.V., Shatsky I.N., and Hellen C.U. Specific interaction of eukaryotic translation initiation factor 3 with the 5' nontranslated regions of hepatitis C virus and classical swine fever virus RNAs. J Virol 72 (1998) 4775-4782
76. Kieft J.S., Zhou K., Jubin R., and Doudna J.A. Mechanism of ribosome recruitment by hepatitis C IRES RNA. RNA 7 (2001) 194-206
77. Ali N., and Siddiqui A. Interaction of polypyrimidine tract-binding protein with the 5' noncoding region of the hepatitis C virus RNA genome and its functional requirement in internal initiation of translation. J Virol 69 (1995) 6367-6375
78. Hahm B., Kim Y.K., Kim J.H., Kim T.Y., and Jang S.K. Heterogeneous nuclear ribonucleoprotein L interacts with the 3' border of the internal ribosomal entry site of hepatitis C virus. J Virol 72 (1998) 8782-8788
79. Ali N., and Siddiqui A. The La antigen binds 5' noncoding region of the hepatitis C virus RNA in the context of the initiator AUG codon and stimulates internal ribosome entry site-mediated translation. Proc Natl Acad Sci U S A 94 (1997) 2249-2254
80. Spangberg K., and Schwartz S. Poly(C)-binding protein interacts with the hepatitis C virus 5' untranslated region. J Gen Virol 80 (1999) 1371-1376
81. Kim J.H., Paek K.Y., Ha S.H., Cho S., Choi K., Kim C.S., Ryu S.H., and Jang S.K. A cellular RNA-binding protein enhances internal ribosomal entry site-dependent translation through an interaction downstream of the hepatitis C virus polyprotein initiation codon. Mol Cell Biol 24 (2004) 7878-7890
82. Zhang J., Yamada O., Yoshida H., Iwai T., and Araki H. Autogenous translational inhibition of core protein: implication for switch from translation to RNA replication in hepatitis C virus. Virology 293 (2002) 141-150
83. Kato J., Kato N., Yoshida H., Ono-Nita S.K., Shiratori Y., and Omata M. Hepatitis C virus NS4A and NS4B proteins suppress translation in vivo. J Med Virol 66 (2002) 187-199
84. Kou Y.H., Chou S.M., Wang Y.M., Chang Y.T., Huang S.Y., Jung M.Y., Huang Y.H., Chen M.R., Chang M.F., and Chang S.C. Hepatitis C virus NS4A inhibits cap-dependent and the viral IRES-mediated translation through interacting with eukaryotic elongation factor 1A. J Biomed Sci 13 (2006) 861-874
85. Imbert I., Dimitrova M., Kien F., Kieny M.P., and Schuster C. Hepatitis C virus IRES efficiency is unaffected by the genomic RNA 3'NTR even in the presence of viral structural or non-structural proteins. J Gen Virol 84 (2003) 1549-1557
86. Wang H., Shen X.T., Ye R., Lan S.Y., Xiang L., and Yuan Z.H. Roles of the polypyrimidine tract and 3' noncoding region of hepatitis C virus RNA in the internal ribosome entry site-mediated translation. Arch Virol 150 (2005) 1085-1099
87. Song Y., Friebe P., Tzima E., Junemann C., Bartenschlager R., and Niepmann M. The hepatitis C virus RNA 3'-untranslated region strongly enhances translation directed by the internal ribosome entry site. J Virol 80 (2006) 11579-11588
88. Bradrick S.S., Walters R.W., and Gromeier M. The hepatitis C virus 3'-untranslated region or a poly(A) tract promote efficient translation subsequent to the initiation phase. Nucleic Acids Res 34 (2006) 1293-1303
89. Brown-Driver V., Eto T., Lesnik E., Anderson K.P., and Hanecak R.C. Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 9 (1999) 145-154
90. Hanecak R., Brown-Driver V., Fox M.C., Azad R.F., Furusako S., Nozaki C., Ford C., Sasmor H., and Anderson K.P. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol 70 (1996) 5203-5212
91. Zhang H., Hanecak R., Brown-Driver V., Azad R., Conklin B., Fox M.C., and Anderson K.P. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob Agents Chemother 43 (1999) 347-353
92. McHutchison J.G., Patel K., Pockros P., Nyberg L., Pianko S., Yu R.Z., Dorr F.A., and Kwoh T.J. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J Hepatol 44 (2006) 88-96
93. Soler M., McHutchison J.G., Kwoh T.J., Dorr F.A., and Pawlotsky J.M. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antivir Ther 9 (2004) 953-968
94. Sakamoto N., Wu C.H., and Wu G.Y. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 98 (1996) 2720-2728
95. Macejak D.G., Jensen K.L., Jamison S.F., Domenico K., Roberts E.C., Chaudhary N., von Carlowitz I., Bellon L., Tong M.J., Conrad A., Pavco P.A., and Blatt L.M. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology 31 (2000) 769-776
96. Gonzalez-Carmona M.A., Schussler S., Serwe M., Alt M., Ludwig J., Sproat B.S., Steigerwald R., Hoffmann P., Quasdorff M., Schildgen O., and Caselmann W.H. Hammerhead ribozymes with cleavage site specificity for NUH and NCH display significant anti-hepatitis C viral effect in vitro and in recombinant HepG2 and CCL13 cells. J Hepatol 44 (2006) 1017-1025
97. Jarczak D., Korf M., Beger C., Manns M.P., and Kruger M. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons. FEBS J 272 (2005) 5910-5922
98. Heptazyme. Drug News Perspect 13 (2000) 112
99. Hamazaki H., Ujino S., Miyano-Kurosaki N., Shimotohno K., and Takaku H. Inhibition of hepatitis C virus RNA replication by short hairpin RNA synthesized by T7 RNA polymerase in hepatitis C virus subgenomic replicons. Biochem Biophys Res Commun 343 (2006) 988-994
100. Kanda T., Steele R., Ray R., and Ray R.B. Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect. J Virol 81 (2007) 669-676
101. Korf M., Meyer A., Jarczak D., Beger C., Manns M.P., and Kruger M. Inhibition of HCV subgenomic replicons by siRNAs derived from plasmids with opposing U6 and H1 promoters. J Viral Hepat 14 (2007) 122-132
102. Kronke J., Kittler R., Buchholz F., Windisch M.P., Pietschmann T., Bartenschlager R., and Frese M. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J Virol 78 (2004) 3436-3446
103. Prabhu R., Garry R.F., and Dash S. Small interfering RNA targeted to stem-loop II of the 5' untranslated region effectively inhibits expression of six HCV genotypes. Virol J 3 (2006) 100
104. Grakoui A., Wychowski C., Lin C., Feinstone S.M., and Rice C.M. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67 (1993) 1385-1395
105. Grakoui A., McCourt D.W., Wychowski C., Feinstone S.M., and Rice C.M. A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A 90 (1993) 10583-10587
106. Hijikata M., Shimizu Y.K., Kato H., Iwamoto A., Shih J.W., Alter H.J., Purcell R.H., and Yoshikura H. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 67 (1993) 1953-1958
107. Lorenz I.C., Marcotrigiano J., Dentzer T.G., and Rice C.M. Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 442 (2006) 831-835
108. Franck N., Le Seyec J., Guguen-Guillouzo C., and Erdtmann L. Hepatitis C virus NS2 protein is phosphorylated by the protein kinase CK2 and targeted for degradation to the proteasome. J Virol 79 (2005) 2700-2708
109. Kim J.L., Morgenstern K.A., Lin C., Fox T., Dwyer M.D., Landro J.A., Chambers S.P., Markland W., Lepre C.A., O'Malley E.T., Harbeson S.L., Rice C.M., Murcko M.A., Caron P.R., and Thomson J.A. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87 (1996) 343-355
110. Love R.A., Parge H.E., Wickersham J.A., Hostomsky Z., Habuka N., Moomaw E.W., Adachi T., and Hostomska Z. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87 (1996) 331-342
111. Yan Y., Li Y., Munshi S., Sardana V., Cole J.L., Sardana M., Steinkuehler C., Tomei L., De Francesco R., Kuo L.C., and Chen Z. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 7 (1998) 837-847
112. Bartenschlager R., Ahlborn-Laake L., Mous J., and Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 67 (1993) 3835-3844
113. Grakoui A., McCourt D.W., Wychowski C., Feinstone S.M., and Rice C.M. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol 67 (1993) 2832-2843
114. Tomei L., Failla C., Santolini E., De Francesco R., and La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 67 (1993) 4017-4026
115. Tanji Y., Hijikata M., Satoh S., Kaneko T., and Shimotohno K. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. J Virol 69 (1995) 1575-1581
116. Bartenschlager R., Lohmann V., Wilkinson T., and Koch J.O. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J Virol 69 (1995) 7519-7528
117. Lin C., Thomson J.A., and Rice C.M. A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J Virol 69 (1995) 4373-4380
118. McLauchlan J., Lemberg M.K., Hope G., and Martoglio B. Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J 21 (2002) 3980-3988
119. Vauloup-Fellous C., Pene V., Garaud-Aunis J., Harper F., Bardin S., Suire Y., Pichard E., Schmitt A., Sogni P., Pierron G., Briand P., and Rosenberg A.R. Signal peptide peptidase-catalyzed cleavage of hepatitis C virus core protein is dispensable for virus budding but destabilizes the viral capsid. J Biol Chem 281 (2006) 27679-27692
120. Yasui K., Wakita T., Tsukiyama-Kohara K., Funahashi S.I., Ichikawa M., Kajita T., Moradpour D., Wands J.R., and Kohara M. The native form and maturation process of hepatitis C virus core protein. J Virol 72 (1998) 6048-6055
121. Penin F., Dubuisson J., Rey F.A., Moradpour D., and Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 39 (2004) 5-19
122. Choukhi A., Pillez A., Drobecq H., Sergheraert C., Wychowski C., and Dubuisson J. Characterization of aggregates of hepatitis C virus glycoproteins. J Gen Virol 80 (1999) 3099-3107
123. Bartenschlager R., and Lohmann V. Replication of the hepatitis C virus. Baillieres Best Pract Res Clin Gastroenterol 14 (2000) 241-254
124. Lindenbach B.D., and Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 436 (2005) 933-938
125. Hinrichsen H., Benhamou Y., Wedemeyer H., Reiser M., Sentjens R.E., Calleja J.L., Forns X., Erhardt A., Cronlein J., Chaves R.L., Yong C.L., Nehmiz G., and Steinmann G.G. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127 (2004) 1347-1355
126. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Bos M., Cameron D.R., Cartier M., Cordingley M.G., Faucher A.M., Goudreau N., Kawai S.H., Kukolj G., Lagace L., LaPlante S.R., Narjes H., Poupart M.A., Rancourt J., Sentjens R.E., St. George R., Simoneau B., Steinmann G., Thibeault D., Tsantrizos Y.S., Weldon S.M., Yong C.L., and Llinas-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-189
127. Reiser M., Hinrichsen H., Benhamou Y., Reesink H.W., Wedemeyer H., Avendano C., Riba N., Yong C.L., Nehmiz G., and Steinmann G.G. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41 (2005) 832-835
128. Lin C., Gates C.A., Rao B.G., Brennan D.L., Fulghum J.R., Luong Y.P., Frantz J.D., Lin K., Ma S., Wei Y.Y., Perni R.B., and Kwong A.D. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 280 (2005) 36784-36791
129. Lin C., Lin K., Luong Y.P., Rao B.G., Wei Y.Y., Brennan D.L., Fulghum J.R., Hsiao H.M., Ma S., Maxwell J.P., Cottrell K.M., Perni R.B., Gates C.A., and Kwong A.D. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 279 (2004) 17508-17514
130. Lu L., Pilot-Matias T.J., Stewart K.D., Randolph J.T., Pithawalla R., He W., Huang P.P., Klein L.L., Mo H., and Molla A. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 48 (2004) 2260-2266
131. Reesink H.W., Zeuzem S., Weegink C.J., Forestier N., van Vliet A., van de Wetering de Rooij J., McNair L., Purdy S., Kauffman R., Alam J., and Jansen P.L. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131 (2006) 997-1002
132. Sarrazin C., Kieffer T.L., Bartels D., Hanzelka B., Muh U., Welker M., Wincheringer D., Zhou Y., Chu H.M., Lin C., Weegink C.J., Reesink H.W., Zeuzem S., and Kwong A.D. Dynamic HCV genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir (VX-950). Gastroenterology (2007) In press.
133. Rodriguez-Torres M., Lawitz E., Muir A.J., Keane J., Kieffer T.L., McNair L., and McHutchison J.G. Current status of subjects receiving peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) follow-on therapy after 28-day treatment with the hepatitis C protease inhibitor telaprevir (VX-950), PEG-IFN and RBV. Hepatology 44 Suppl 2 (2006) 532A
134. McHutchison J.G., Everson G.T., Gordon S., Jacobson I., Kauffman R., McNair L., and Muir A.J. Results of an interim analysis of a phase II study of telaprevir (VX-950) with peginterferon alfa-2a and ribavirin in previously untreated subjects with hepatitis C. J Hepatol (2007) In press.
135. Malcolm B.A., Liu R., Lahser F., Agrawal S., Belanger B., Butkiewicz N., Chase R., Gheyas F., Hart A., Hesk D., Ingravallo P., Jiang C., Kong R., Lu J., Pichardo J., Prongay A., Skelton A., Tong X., Venkatraman S., Xia E., Girijavallabhan V., and Njoroge F.G. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of α interferon in replicon cells. Antimicrob Agents Chemother 50 (2006) 1013-1020
136. Venkatraman S., Bogen S.L., Arasappan A., Bennett F., Chen K., Jao E., Liu Y.T., Lovey R., Hendrata S., Huang Y., Pan W., Parekh T., Pinto P., Popov V., Pike R., Ruan S., Santhanam B., Vibulbhan B., Wu W., Yang W., Kong J., Liang X., Wong J., Liu R., Butkiewicz N., Chase R., Hart A., Agrawal S., Ingravallo P., Pichardo J., Kong R., Baroudy B., Malcolm B., Guo Z., Prongay A., Madison V., Broske L., Cui X., Cheng K.C., Hsieh Y., Brisson J.M., Prelusky D., Korfmacher W., White R., Bogdanowich-Knipp S., Pavlovsky A., Bradley P., Saksena A.K., Ganguly A., Piwinski J., Girijavallabhan V., and Njoroge F.G. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1 -dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimeth yl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 49 (2006) 6074-6086
137. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., and Malcolm B.A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70 (2006) 28-38
138. Sarrazin C., Rouzier R., Wagner F., Forestier N., Larrey D., Gupta S., Hussain M., Shah A., Cutler D., Zhang J., and Zeuzem S. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alfa-2b for genotype 1 non-responders. Gastroenterology (2007) In press.
139. Pottage J.C., Lawitz E., Mazur D., Wyles D., Vargas H., Ghalib R., Gugliotti R., Donohue M., and Robison H. Short-term antiviral activity and safety of ACH-806 (GS-9132), an NS4A antagonist, in HCV genotype 1 infected individuals. J Hepatol (2007) In press.
140. Seiwert S., Andrews S.W., Yang H., Tan H., Marafino B., Rieger R., Franklin R.B., Pheneger J., Lee P.A., Jiang Y., Kennedy A.L., Wenglowsky S.M., Madduru M.R., Doherty G.A., Condroski K.R., Lemieux C., Pieti Opie L., Sullivan F., Neitzel N., Hingorani G.P., Otten J., Brandhuber B., Vigers G., Josey J.A., and Blatt L.M. Preclinical characteristics of ITMN 191, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development. Gastroenterology 130 Suppl 2 (2006) A834
141. Ivashkina N., Wolk B., Lohmann V., Bartenschlager R., Blum H.E., Penin F., and Moradpour D. The hepatitis C virus RNA-dependent RNA polymerase membrane insertion sequence is a transmembrane segment. J Virol 76 (2002) 13088-13093
142. Schmidt-Mende J., Bieck E., Hugle T., Penin F., Rice C.M., Blum H.E., and Moradpour D. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 276 (2001) 44052-44063
143. Moradpour D., Brass V., Bieck E., Friebe P., Gosert R., Blum H.E., Bartenschlager R., Penin F., and Lohmann V. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. J Virol 78 (2004) 13278-13284
144. Ago H., Adachi T., Yoshida A., Yamamoto M., Habuka N., Yatsunami K., and Miyano M. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure Fold Des 7 (1999) 1417-1426
145. Bressanelli S., Tomei L., Roussel A., Incitti I., Vitale R.L., Mathieu M., De Francesco R., and Rey F.A. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A 96 (1999) 13034-13039
146. Lesburg C.A., Cable M.B., Ferrari E., Hong Z., Mannarino A.F., and Weber P.C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 6 (1999) 937-943
147. Evans M.J., Rice C.M., and Goff S.P. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A 101 (2004) 13038-13043
148. Tu H., Gao L., Shi S.T., Taylor D.R., Yang T., Mircheff A.K., Wen Y., Gorbalenya A.E., Hwang S.B., and Lai M.M. Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein. Virology 263 (1999) 30-41
149. Gao L., Aizaki H., He J.W., and Lai M.M. Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. J Virol 78 (2004) 3480-3488
150. Ma S., Boerner J.E., TiongYip C., Weidmann B., Ryder N.S., Cooreman M.P., and Lin K. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with α interferon. Antimicrob Agents Chemother 50 (2006) 2976-2982
151. Nakagawa M., Sakamoto N., Tanabe Y., Koyama T., Itsui Y., Takeda Y., Chen C.H., Kakinuma S., Oooka S., Maekawa S., Enomoto N., and Watanabe M. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 129 (2005) 1031-1041
152. Watashi K., Ishii N., Hijikata M., Inoue D., Murata T., Miyanari Y., and Shimotohno K. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 19 (2005) 111-122
153. Brass V., Bieck E., Montserret R., Wolk B., Hellings J.A., Blum H.E., Penin F., and Moradpour D. An amino-terminal amphipathic α-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J Biol Chem 277 (2002) 8130-8139
154. Elazar M., Cheong K.H., Liu P., Greenberg H.B., Rice C.M., and Glenn J.S. Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol 77 (2003) 6055-6061
155. Penin F., Brass V., Appel N., Ramboarina S., Montserret R., Ficheux D., Blum H.E., Bartenschlager R., and Moradpour D. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem 279 (2004) 40835-49843
156. Shi S.T., Lee K.J., Aizaki H., Hwang S.B., and Lai M.M. Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. J Virol 77 (2003) 4160-4168
157. Appel N., Pietschmann T., and Bartenschlager R. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J Virol 79 (2005) 3187-3194
158. Ye J., Wang C., Sumpter Jr. R., Brown M.S., Goldstein J.L., and Gale Jr. M. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 100 (2003) 15865-15870
159. Wang C., Gale Jr. M., Keller B.C., Huang H., Brown M.S., Goldstein J.L., and Ye J. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 18 (2005) 425-434
160. Kim J.L., Morgenstern K.A., Griffith J.P., Dwyer M.D., Thomson J.A., Murcko M.A., Lin C., and Caron P.R. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 6 (1998) 89-100
161. Yao N., Hesson T., Cable M., Hong Z., Kwong A.D., Le H.V., and Weber P.C. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 4 (1997) 463-467
162. Cho H.S., Ha N.C., Kang L.W., Chung K.M., Back S.H., Jang S.K., and Oh B.H. Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA. J Biol Chem 273 (1998) 15045-15052
163. Tai C.L., Chi W.K., Chen D.S., and Hwang L.H. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J Virol 70 (1996) 8477-8484
164. Gwack Y., Kim D.W., Han J.H., and Choe J. DNA helicase activity of the hepatitis C virus nonstructural protein 3. Eur J Biochem 250 (1997) 47-54
165. Zhang C., Cai Z., Kim Y.C., Kumar R., Yuan F., Shi P.Y., Kao C., and Luo G. Stimulation of hepatitis C virus (HCV) nonstructural protein 3 (NS3) helicase activity by the NS3 protease domain and by HCV RNA-dependent RNA polymerase. J Virol 79 (2005) 8687-8697
166. Hugle T., Fehrmann F., Bieck E., Kohara M., Krausslich H.G., Rice C.M., Blum H.E., and Moradpour D. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology 284 (2001) 70-81
167. Lundin M., Monne M., Widell A., Von Heijne G., and Persson M.A. Topology of the membrane-associated hepatitis C virus protein NS4B. J Virol 77 (2003) 5428-5438
168. Elazar M., Liu P., Rice C.M., and Glenn J.S. An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J Virol 78 (2004) 11393-11400
169. Egger D., Wolk B., Gosert R., Bianchi L., Blum H.E., Moradpour D., and Bienz K. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 76 (2002) 5974-5984
170. Gretton S.N., Taylor A.I., and McLauchlan J. Mobility of the hepatitis C virus NS4B protein on the endoplasmic reticulum membrane and membrane-associated foci. J Gen Virol 86 (2005) 1415-1421
171. Piccininni S., Varaklioti A., Nardelli M., Dave B., Raney K.D., and McCarthy J.E. Modulation of the hepatitis C virus RNA-dependent RNA polymerase activity by the non-structural (NS) 3 helicase and the NS4B membrane protein. J Biol Chem 277 (2002) 45670-45679
172. Kolykhalov A.A., Feinstone S.M., and Rice C.M. Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. J Virol 70 (1996) 3363-3371
173. Tanaka T., Kato N., Cho M.J., and Shimotohno K. A novel sequence found at the 3' terminus of hepatitis C virus genome. Biochem Biophys Res Commun 215 (1995) 744-749
174. Tanaka T., Kato N., Cho M.J., Sugiyama K., and Shimotohno K. Structure of the 3' terminus of the hepatitis C virus genome. J Virol 70 (1996) 3307-3312
175. Cheng J.C., Chang M.F., and Chang S.C. Specific interaction between the hepatitis C virus NS5B RNA polymerase and the 3' end of the viral RNA. J Virol 73 (1999) 7044-7049
176. Lee H., Shin H., Wimmer E., and Paul A.V. cis-acting RNA signals in the NS5B C-terminal coding sequence of the hepatitis C virus genome. J Virol 78 (2004) 10865-10877
177. Friebe P., Boudet J., Simorre J.P., and Bartenschlager R. Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication. J Virol 79 (2005) 380-392
178. You S., Stump D.D., Branch A.D., and Rice C.M. A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol 78 (2004) 1352-1366
179. Friebe P., and Bartenschlager R. Genetic analysis of sequences in the 3' nontranslated region of hepatitis C virus that are important for RNA replication. J Virol 76 (2002) 5326-5338
180. Ito T., and Lai M.M. Determination of the secondary structure of and cellular protein binding to the 3'-untranslated region of the hepatitis C virus RNA genome. J Virol 71 (1997) 8698-8706
181. Yi M., and Lemon S.M. 3' Nontranslated RNA signals required for replication of hepatitis C virus RNA. J Virol 77 (2003) 3557-3568
182. Yi M., and Lemon S.M. Structure-function analysis of the 3' stem-loop of hepatitis C virus genomic RNA and its role in viral RNA replication. RNA 9 (2003) 331-345
183. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., and Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309 (2005) 1577-1581
184. Bartenschlager R., Frese M., and Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 63 (2004) 171-180
185. Kapadia S.B., and Chisari F.V. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 102 (2005) 2561-2566
186. Behrens S.E., Tomei L., and De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 15 (1996) 12-22
187. Zhong W., Uss A.S., Ferrari E., Lau J.Y., and Hong Z. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. J Virol 74 (2000) 2017-2022
188. Astier-Gin T., Bellecave P., Litvak S., and Ventura M. Template requirements and binding of hepatitis C virus NS5B polymerase during in vitro RNA synthesis from the 3'-end of virus minus-strand RNA. FEBS J 272 (2005) 3872-3886
189. Luo G. Cellular proteins bind to the poly(U) tract of the 3' untranslated region of hepatitis C virus RNA genome. Virology 256 (1999) 105-118
190. Luo G. Molecular virology of hepatitis C virus. In: Coloacino J.M., and Heinz B.A. (Eds). Hepatitis prevention and treatment (2004), Birkhausser, Basel 67-85
191. Chang K.S., and Luo G. The polypyrimidine tract-binding protein (PTB) is required for efficient replication of hepatitis C virus (HCV) RNA. Virus Res 115 (2006) 1-8
192. Afdhal N.H., O'Brien C., Godofsky E., Rodriguez-Torres M., Pappas S.C., Pockros P., Lawitz E., Bzowej N., Rustgi V., Sulkowski M., Sherman K.E., Jacobson I., Chao G., Knox S., Pietropaolo K., and Brown N. Valopicitabine (NM283), alone or with peg-interferon, compared to peg-interferon/ribavirin (PEGIFN/RBV) retreatment in hepatitis C patients with prior non-response to PEGIFN/RBV: week 24 results. J Hepatol 44 Suppl 2 (2006) S19
193. Coelmont L., Paeshuyse J., Windisch M.P., De Clercq E., Bartenschlager R., and Neyts J. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother 50 (2006) 3444-3446
194. Roberts S., Cooksley G., Dore G., Robson R., Shaw D., Berns H., Brandl M., Fettner S., Hill G., Ipe D., Klumpp K., Mannino M., O'Mara E., Tu Y., and Washington C. Results of a phase 1b, multiple dose study of R1626, a novel nucleoside analogue targeting HCV polymerase in chronic HCV genotype 1 patients. Hepatology 44 Suppl 1 (2006) 692A
195. Chandra P., Raible D., Harper D., Speth J., Villano S., and Bichier G. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in patients with chronic hepatitis C virus: preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. Gastroenterology 130 Suppl 2 (2006) A748
196. Villano S.A., Raible D., Harper D., Speth J., Chandra P., Shaw P., and Bichier G. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pagylated interferon alfa-2b in treatment-naive patients with chronic HCV. J Hepatol (2007) In press.
197. Paeshuyse J., Kaul A., De Clercq E., Rosenwirth B., Dumont J.M., Scalfaro P., Bartenschlager R., and Neyts J. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43 (2006) 761-770
198. Flisiak R., Orban A., Kierkus J., Stanczak J., Cielnak I., Stanczak G.P., Wiercinska-Drapalo A., Siwak E., Higersberger J., Aeschlimann C., Grosgurin P., Nicolas V., Dumont J.M., Porchet H., Crabbé R., and Scalfaro P. The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naïve HIV/HCV co-infected subjects. Hepatology 44 Suppl 1 (2006) A609
199. Goto K., Watashi K., Murata T., Hishiki T., Hijikata M., and Shimotohno K. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem Biophys Res Commun 343 (2006) 879-884
200. Carroll S.S., and Olsen D.B. Nucleoside analog inhibitors of hepatitis C virus replication. Infect Disord Drug Targets 6 (2006) 17-29
201. Koch U., and Narjes F. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Infect Disord Drug Targets 6 (2006) 31-41
202. Maga G., Gemma S., Fattorusso C., Locatelli G.A., Butini S., Persico M., Kukreja G., Romano M.P., Chiasserini L., Savini L., Novellino E., Nacci V., Spadari S., and Campiani G. Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. Biochemistry 44 (2005) 9637-9644
203. Hwang B., Cho J.S., Yeo H.J., Kim J.H., Chung K.M., Han K., Jang S.K., and Lee S.W. Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA 10 (2004) 1277-1290
204. Harada S., Watanabe Y., Takeuchi K., Suzuki T., Katayama T., Takebe Y., Saito I., and Miyamura T. Expression of processed core protein of hepatitis C virus in mammalian cells. J Virol 65 (1991) 3015-3021
205. Santolini E., Migliaccio G., and La Monica N. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol 68 (1994) 3631-3641
206. Chang S.C., Yen J.H., Kang H.Y., Jang M.H., and Chang M.F. Nuclear localization signals in the core protein of hepatitis C virus. Biochem Biophys Res Commun 205 (1994) 1284-1290
207. Suzuki R., Matsuura Y., Suzuki T., Ando A., Chiba J., Harada S., Saito I., and Miyamura T. Nuclear localization of the truncated hepatitis C virus core protein with its hydrophobic C terminus deleted. J Gen Virol 76 (1995) 53-61
208. Suzuki R., Sakamoto S., Tsutsumi T., Rikimaru A., Tanaka K., Shimoike T., Moriishi K., Iwasaki T., Mizumoto K., Matsuura Y., Miyamura T., and Suzuki T. Molecular determinants for subcellular localization of hepatitis C virus core protein. J Virol 79 (2005) 1271-1281
209. Schwer B., Ren S., Pietschmann T., Kartenbeck J., Kaehlcke K., Bartenschlager R., Yen T.S., and Ott M. Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif. J Virol 78 (2004) 7958-7968
210. Baumert T.F., Ito S., Wong D.T., and Liang T.J. Hepatitis C virus structural proteins assemble into virus-like particles in insect cells. J Virol 72 (1998) 3827-3836
211. Blanchard E., Brand D., Trassard S., Goudeau A., and Roingeard P. Hepatitis C virus-like particle morphogenesis. J Virol 76 (2002) 4073-4079
212. Blanchard E., Hourioux C., Brand D., Ait-Goughoulte M., Moreau A., Trassard S., Sizaret P.Y., Dubois F., and Roingeard P. Hepatitis C virus-like particle budding: role of the core protein and importance of its Asp111. J Virol 77 (2003) 10131-10138
213. Ezelle H.J., Markovic D., and Barber G.N. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J Virol 76 (2002) 12325-12334
214. Klein K.C., Polyak S.J., and Lingappa J.R. Unique features of hepatitis C virus capsid formation revealed by de novo cell-free assembly. J Virol 78 (2004) 9257-9269
215. Pietschmann T., Lohmann V., Kaul A., Krieger N., Rinck G., Rutter G., Strand D., and Bartenschlager R. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 76 (2002) 4008-4021
216. Kunkel M., Lorinczi M., Rijnbrand R., Lemon S.M., and Watowich S.J. Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein. J Virol 75 (2001) 2119-2129
217. Shimoike T., Mimori S., Tani H., Matsuura Y., and Miyamura T. Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation. J Virol 73 (1999) 9718-9725
218. Tanaka Y., Shimoike T., Ishii K., Suzuki R., Suzuki T., Ushijima H., Matsuura Y., and Miyamura T. Selective binding of hepatitis C virus core protein to synthetic oligonucleotides corresponding to the 5' untranslated region of the viral genome. Virology 270 (2000) 229-236
219. Mizuno M., Yamada G., Tanaka T., Shimotohno K., Takatani M., and Tsuji T. Virion-like structures in HeLa G cells transfected with the full-length sequence of the hepatitis C virus genome. Gastroenterology 109 (1995) 1933-1940
220. Dash S., Halim A.B., Tsuji H., Hiramatsu N., and Gerber M.A. Transfection of HepG2 cells with infectious hepatitis C virus genome. Am J Pathol 151 (1997) 363-373
221. Serafino A., Valli M.B., Andreola F., Crema A., Ravagnan G., Bertolini L., and Carloni G. Suggested role of the Golgi apparatus and endoplasmic reticulum for crucial sites of hepatitis C virus replication in human lymphoblastoid cells infected in vitro. J Med Virol 70 (2003) 31-41
222. Durantel D., Carrouee-Durantel S., Branza-Nichita N., Dwek R.A., and Zitzmann N. Effects of interferon, ribavirin, and iminosugar derivatives on cells persistently infected with noncytopathic bovine viral diarrhea virus. Antimicrob Agents Chemother 48 (2004) 497-504
223. Whitby K., Taylor D., Patel D., Ahmed P., and Tyms A.S. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. Antivir Chem Chemother 15 (2004) 141-151
224. Pawlotsky J.M. Treatment of hepatitis C: don't put all your eggs in one basket!. Gastroenterology (2007) In press.